Search results
Results from the WOW.Com Content Network
Glecaprevir (INN, [1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. [2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir.
Sofosbuvir also is an excellent example of both the benefit and the challenge of specialty medications. On one hand, this agent offers up to a 95% response rate as part of an interferon-free treatment regimen for hepatitis C. Generally speaking, it is more effective and better tolerated than alternative treatments.
Treatment of people aged twelve years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy [2]
In fact, the rate of new hepatitis C cases more than quadrupled over the last decade, according to a study conducted by the Centers for Disease Control and Prevention (CDC). Dr. Dr.
Name Lifetime Comments Pamela Anderson: 1967– Famous for her role as C.J. Parker on the television series Baywatch. She has, since late 2015 had a successful treatment of hepatitis C, and has been cured of the disease. [10] Stanley Fafara: 1943–2003 Child actor who played "Whitey" on Leave it to Beaver. He was a recovering heroin addict who ...
Bristol-Myers Squibb's (NYS: BMY) latest data on its current hepatitis C drugs explain why the pharma needed to purchase Inihibitex (NAS: INHX) . A combination of its drugs -- daclatasvir and ...
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [2] [5] [6] [7] It combines sofosbuvir and velpatasvir. [2] [5] [6] It is more than 90% effective for hepatitis C genotypes one through six. [2]
Sofosbuvir is a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus. Gilead Sciences has received FDA priority review status for its New Drug Application ...